argenx SE (ARGX)
Automate Your Wheel Strategy on ARGX
With Tiblio's Option Bot, you can configure your own wheel strategy including ARGX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARGX
- Rev/Share 35.8501
- Book/Share 91.8856
- PB 6.2388
- Debt/Equity 0.0071
- CurrentRatio 7.2891
- ROIC -0.0467
- MktCap 35003026296.0
- FreeCF/Share -1.2972
- PFCF -450.9285
- PE 42.6034
- Debt/Assets 0.0063
- DivYield 0
- ROE 0.165
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ARGX | Robert W. Baird | Neutral | Outperform | -- | $680 | May 13, 2025 |
| Upgrade | ARGX | Bernstein | Market Perform | Outperform | -- | -- | March 17, 2025 |
| Upgrade | ARGX | Deutsche Bank | Sell | Hold | -- | -- | March 12, 2025 |
| Downgrade | ARGX | Deutsche Bank | Hold | Sell | -- | -- | Jan. 17, 2025 |
| Resumed | ARGX | Raymond James | -- | Strong Buy | -- | $605 | Oct. 10, 2024 |
| Downgrade | ARGX | Deutsche Bank | Buy | Hold | -- | -- | Oct. 4, 2024 |
News
EXEL vs. ARGX: Which Stock Is the Better Value Option?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Argenx (ARGX) Upgraded to Buy: Here's Why
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Argenx (ARGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Argenx Q1 Earnings: Less Than Perfect Report Gets Punished
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Positive
Shares of argenx declined yesterday as Vyvgart missed investors' expectations. Vyvgart saw the usual negative seasonal headwinds in the U.S. in the first quarter that were further exacerbated by the Medicare redesign. Underlying demand was strong across the globe, and Vyvgart looks well positioned for continued growth, which should be helped by the approval of the PFS and international indication expansion.
Read More
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update. “We continue to execute …
Read More
AZN or ARGX: Which Is the Better Value Stock Right Now?
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Astrazeneca (AZN) or argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
argenx to Present at BofA Securities 2025 Health Care Conference
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
May 6, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, and members of the management team will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. PT.
Read More
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
May 1, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update.
Read More
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two months April 28, 2025, 07:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has …
Read More
Wall Street Analysts Believe Argenx (ARGX) Could Rally 25.8%: Here's is How to Trade
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Argenx (ARGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
Stock Picks From Seeking Alpha's March 2025 New Analysts
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Neutral
In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT, financials, utilities, materials, and mining—and provided ratings ranging from Strong Sell to Strong Buy. Top picks include C3.ai, Robinhood, Central Puerto, CF Industries, and Kyndryl.
Read More
JAZZ or ARGX: Which Is the Better Value Stock Right Now?
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains?
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Positive
argenx reported Q4 earnings today. Vyvgart's strong Q4 2024 performance, driven by the U.S. CIDP launch, positions it for continued growth with upcoming launches and approvals in Europe, Japan, and the U.S. The sales outlook for 2025 looks strong, and I expect Vyvgart to once again exceed Street expectations. The pipeline catalyst calendar is light for 2025, and several far more important readouts of Vyvgart and one of empasiprubart are expected in 2026.
Read More
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA (gMG and CIDP) on track for April 10 10 Phase 3 and 10 Phase 2 studies across pipeline ongoing in 2025, positioning for next wave of growth Recognized one-time tax benefit of $725 million related to previously unrecognized deferred tax assets Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 27, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & …
Read More
argenx to Present at TD Cowen 45th Annual Healthcare Conference
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
February 25, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET.
Read More
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
February 20, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 27, 2025 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2024 financial results and provide a fourth quarter business update.
Read More
About argenx SE (ARGX)
- IPO Date 2017-05-18
- Website https://www.argenx.com
- Industry Biotechnology
- CEO Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
- Employees 1599